A Novel Hybrid Additive Manufacturing Process for Drug Delivery Systems with Locally Incorporated Drug Depots
A Novel Hybrid Additive Manufacturing Process for Drug Delivery Systems with Locally Incorporated Drug Depots
复制标题
DOI：
10.3390/pharmaceutics11120661
复制
发表时间：
2019-12-01
期刊：
影响因子：
5.4
通讯作者：
Seitz, Hermann
中科院分区：
文献类型：
--
作者：
Konasch, Jan;Riess, Alexander;Seitz, Hermann
在这里，我们提出了一种新的混合增材制造（AM）工艺，以创建具有选择性合并药物仓库的药物递送系统（DDS）。DDS的基质是通过立体光刻（SLA）生成的，而药物贮库是使用喷墨打印加载的。在现有的SLA测试装置中成功地实现了SLA与喷墨打印相结合的新型AM工艺。在第一项研究中，产生了基于聚（乙二醇）二丙烯酸酯的标本与集成库。作为测试液体，使用蓝色和粉红色油墨溶液。此外，考马斯亮蓝标记的牛血清白蛋白作为模型药物被成功地放置在DDS内的贮库中。新的混合AM工艺使得在基质中放置几种彼此独立的药物成为可能。这允许根据DDS中贮库的大小以及位置来调节药物的释放曲线。
Here, we present a new hybrid additive manufacturing (AM) process to create drug delivery systems (DDSs) with selectively incorporated drug depots. The matrix of a DDS was generated by stereolithography (SLA), whereas the drug depots were loaded using inkjet printing. The novel AM process combining SLA with inkjet printing was successfully implemented in an existing SLA test setup. In the first studies, poly(ethylene glycol) diacrylate-based specimens with integrated depots were generated. As test liquids, blue and pink ink solutions were used. Furthermore, bovine serum albumin labeled with Coomassie blue dye as a model drug was successfully placed in a depot inside a DDS. The new hybrid AM process makes it possible to place several drugs independently of each other within the matrix. This allows adjustment of the release profiles of the drugs depending on the size as well as the position of the depots in the DDS.